上尿路尿路上皮癌根治术前膀胱内灌注化疗:REBACARE试验
这项前瞻性单臂多中心2期试验纳入190例未接受过化疗的原发性上尿路尿路上皮癌患者,术前3小时内单次膀胱内灌注丝裂霉素C 1-2小时,2年膀胱内复发率为24%(95%CI 18-31%),依从性96%,无>2级毒性;无诊断性输尿管镜史者复发风险较历史对照降低。
要点
- 术前膀胱内灌注丝裂霉素C可行且耐受良好,2年膀胱内复发率24%(95%CI 18-31%)。
- 无诊断性输尿管镜史患者复发风险较历史对照降低(HR 0.33,95%CI 0.12-0.87)。
- 诊断性输尿管镜与更高膀胱内复发风险相关,作者建议审慎进行。
核心结论
- 术前膀胱内灌注丝裂霉素C可行且耐受良好,显著降低无诊断性输尿管镜史患者的膀胱内复发风险。
- 作者认为术前灌注是该亚组上尿路尿路上皮癌患者的可行策略,诊断性输尿管镜应审慎进行。
研究设计与样本
- 前瞻性、单臂、多中心2期临床试验,纳入190例未接受过化疗的原发性上尿路尿路上皮癌且无既往或同期膀胱癌患者。
- 干预为术前3小时内单次膀胱内灌注丝裂霉素C 1-2小时。
- 主要终点为2年组织学确诊的膀胱内复发率,目标为较文献数据33.2%降低>40%至<20%。
- 历史对照队列为247例未接受围手术期膀胱内灌注化疗的上尿路尿路上皮癌患者。
主要发现
- 意向性分析2年膀胱内复发率为24%(95%CI 18-31%),符合方案分析为23%(95%CI 13-32%)。
- 多因素分析显示诊断性输尿管镜与更高膀胱内复发风险相关。
- REBACARE队列中无诊断性输尿管镜史患者较历史对照队列膀胱内复发风险降低三倍(HR 0.33,95%CI 0.12-0.87)。
- 术前灌注依从性为96%,未发生>2级毒性。
临床怎么用
- 作者认为术前膀胱内灌注丝裂霉素C是无可诊断性输尿管镜史的上尿路尿路上皮癌患者的可行策略。
- 作者建议诊断性输尿管镜应审慎进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Intravesical instillation of chemotherapy (IIC) after radical surgery for upper urinary tract urothelial carcinoma (UTUC) reduces the risk of intravesical recurrence (IVR). However, compliance is low because of possible extravesical leakage after bladder cuff excision. The aim of this study was to evaluate the efficacy of preoperative IIC in reducing the risk of IVR. METHODS: In this prospective, single-arm, multi-institutional, phase 2 clinical trial, 190 chemonaïve patients with primary UTUC without prior or concurrent bladder cancer received a single intravesical instillation of mitomycin C for 1-2 hr within 3 h before surgery. The primary endpoint was the 2-yr histologically confirmed IVR rate, with a target reduction of >40% (from 33.2% according to literature data to <20%). A historical cohort of 247 patients with UTUC who did not receive perioperative IIC served as the reference. Secondary endpoints included compliance, toxicity, and IVR-free survival, which was analyzed via multivariable Cox regression and stratified by previous diagnostic ureteroscopy (d-URS). KEY FINDINGS AND LIMITATIONS: The 2-yr IVR rate was 24% (95% confidence interval [CI] 18-31%) on intention-to-treat analysis and 23% (95% CI 13-32%) on per-protocol analysis. Multivariable analysis revealed that d-URS was associated with higher IVR risk. In the REBACARE cohort, patients without d-URS had threefold lower IVR risk (hazard ratio 0.33, 95% CI 0.12-0.87) in comparison to the reference cohort. Compliance with preoperative instillation was 96% and no grade >2 toxicity occurred. CONCLUSIONS AND CLINICAL IMPLICATIONS: Preoperative IIC with mitomycin C was feasible and well tolerated and significantly reduced IVR risk for patients without d-URS. These findings suggest that preoperative IIC is a viable strategy for this subset of UTUC patients and that d-URS should be performed judiciously.
引用
- van Doeveren T, Remmers S, Boevé ER, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. 2025. PMID: 39843302. doi:10.1016/j.eururo.2024.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。